HC Wainwright Reaffirms “Neutral” Rating for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports.

A number of other analysts have also issued reports on ATRA. RODMAN&RENSHAW lowered shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 21st. TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. Canaccord Genuity Group decreased their price objective on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a report on Friday, January 17th. Finally, Rodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.75.

Atara Biotherapeutics Stock Down 10.3 %

ATRA opened at $7.37 on Tuesday. The firm’s 50 day moving average is $11.89 and its 200-day moving average is $9.96. Atara Biotherapeutics has a 52-week low of $5.40 and a 52-week high of $39.50. The firm has a market capitalization of $42.45 million, a P/E ratio of -0.29 and a beta of 0.51.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the business earned ($16.50) earnings per share. Equities analysts expect that Atara Biotherapeutics will post -9.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atara Biotherapeutics

Several hedge funds have recently made changes to their positions in ATRA. Geode Capital Management LLC increased its stake in Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 4,043 shares during the period. State Street Corp increased its holdings in Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after buying an additional 7,680 shares during the last quarter. Vestal Point Capital LP grew its position in Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after acquiring an additional 12,677 shares in the last quarter. FMR LLC lifted its stake in shares of Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Atara Biotherapeutics during the 2nd quarter worth about $79,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.